and
viru
andv
highli
pathogen
human
primari
etiolog
agent
hantaviru
cardiopulmonari
syndrom
hcp
south
america
casefat
rate
high
approv
vaccin
specif
therapi
infect
laboratori
recent
develop
replicationcompet
recombin
vesicular
stomat
viru
vsv
base
vaccin
express
glycoprotein
and
viru
place
nativ
vsv
glycoprotein
g
vaccin
highli
efficaci
syrian
hamster
model
hcp
given
day
challeng
andv
given
around
time
challeng
periexposur
even
protect
administ
postexposur
herein
sought
test
durabl
immun
respons
singl
dose
vaccin
syrian
hamster
vaccin
efficaci
hamster
challeng
intranas
andv
month
vaccin
p
anim
significantli
protect
follow
year
vaccin
p
decreas
protect
correl
reduct
measur
neutral
antibodi
respons
suggest
robust
vaccin
schedul
might
requir
provid
longterm
immun
and
viru
andv
new
world
hantaviru
famili
bunyavirida
genu
hantaviru
primari
etiolog
agent
hantaviru
cardiopulmonari
syndrom
hcp
south
america
case
fatal
rate
andv
zoonot
viru
host
longtail
pigmi
rice
rat
oligoryzomi
longicaudatu
upon
transmiss
human
caus
hcp
humantohuman
transmiss
also
document
current
approv
vaccin
specif
treatment
hantavirus
caus
hcp
medic
intervent
larg
support
date
anim
model
recapitul
human
diseas
caus
andv
syrian
hamster
laboratori
recent
report
recombin
replicationcompet
recombin
vesicular
stomat
viru
vsv
base
vaccin
engin
express
glycoprotein
complex
gpc
andv
place
vsv
glycoprotein
g
provid
complet
protect
diseas
hamster
hamster
steril
protect
one
month
singl
dose
vaccin
upon
challeng
consist
lethal
dose
andv
vaccin
also
efficaci
postexposur
hamster
protect
vaccin
administ
one
day
inocul
andv
mechan
vaccin
offer
protect
entir
known
might
differ
depend
time
challeng
postexposur
protect
unlik
reli
gener
neutral
antibodi
vsvvector
express
irrelev
glycoprotein
also
afford
periexposur
protect
andv
challeng
nonetheless
vsvbase
vaccin
platform
known
elicit
strong
humor
immun
respons
vsvandv
system
neutral
antibodi
direct
gpc
like
import
prophylact
vaccin
herein
sought
test
kinet
neutral
respons
elicit
vaccin
test
durat
immun
follow
singledos
vaccin
lethal
diseas
caus
andv
hamster
model
hamster
vaccin
show
statist
signific
increas
p
surviv
challeng
lethal
dose
andv
month
vaccin
vaccin
hamster
surviv
challeng
wherea
singl
anim
unvaccin
hamster
surviv
andv
challeng
figur
convers
month
vaccin
group
significantli
protect
p
compar
control
group
although
vaccin
afford
level
protect
figur
point
singl
vaccin
hamster
develop
sign
diseas
euthan
control
hamster
surviv
inocul
render
result
time
point
insignific
notabl
singl
mock
vaccin
anim
surviv
month
postvaccin
two
surviv
time
point
laboratori
extens
experi
use
syrian
hamster
model
hcp
experi
typic
alway
complet
time
anim
reach
month
age
rare
ever
observ
control
anim
surviv
dose
rout
andv
inocul
control
anim
thu
far
experi
perform
use
stock
viru
prepar
use
studi
suggest
age
like
influenc
immun
statu
might
play
role
natur
protect
diseas
studi
use
older
hamster
result
variabl
lethal
support
older
hamster
might
immun
diseas
although
need
address
experiment
difficult
compar
studi
use
differ
rout
infect
stock
virus
sourc
anim
limit
studi
rel
small
group
size
make
difficult
resolv
differ
potenti
surviv
age
control
anim
discrimin
durabl
vaccin
repeat
studi
use
larger
group
size
well
addit
time
point
would
lend
insight
agerel
affect
surviv
longterm
efficaci
vaccin
examin
kinet
immun
respons
vaccin
cours
studi
obtain
serum
anim
month
anim
remain
month
challeng
experi
postvaccin
sera
test
neutral
activ
perform
frnt
assay
along
sera
unvaccin
anim
none
mockvaccin
anim
develop
measur
neutral
antibodi
data
shown
vaccin
anim
achiev
titer
least
month
three
anim
achiev
titer
figur
two
case
neutral
titer
drop
month
vaccin
singl
anim
develop
diseas
challeng
month
postvaccin
titer
drop
anim
minimum
dilut
use
assay
hamster
develop
diseas
month
postvaccin
neutral
titer
anim
two
hamster
group
also
titer
develop
diseas
wherea
three
anim
titer
least
surviv
hamster
challeng
month
two
titer
three
titer
although
titer
less
observ
protect
nonprotect
anim
month
titer
suggest
greater
age
anim
could
contribut
protect
correl
observ
increas
surviv
nonvaccin
control
anim
group
two
surviv
time
point
one
surviv
month
previou
studi
observ
singl
dose
vaccin
provid
steril
immun
hamster
challeng
day
vaccin
test
whether
surviv
anim
studi
steril
protect
andv
month
postvaccin
perform
elisa
detect
antiandvn
antibodi
tabl
anim
surviv
challeng
mock
vaccin
vaccin
develop
andvn
antibodi
suggest
steril
immun
achiev
differ
could
attribut
longer
time
period
vaccin
challeng
studi
like
relat
observ
decreas
neutral
antibodi
titer
use
differ
rout
inocul
herein
make
difficult
directli
compar
studi
previou
studi
chose
inocul
hamster
intranas
infecti
dose
viru
use
previous
close
mimic
human
exposur
transmiss
oppos
intraperiton
rout
previous
report
mucos
immun
might
difficult
achiev
confer
steril
immun
might
allow
viru
infect
cell
respiratori
tract
neutral
humor
immun
respons
elicit
vaccin
vaccin
vsvbase
vaccin
vector
provid
potent
longterm
protect
system
mice
vaccin
vsv
express
spike
protein
sever
acut
respiratori
syndrom
viru
protect
lethal
challeng
month
later
follow
singl
dose
administr
vsv
express
ha
influenza
viru
protect
year
vaccin
although
mice
given
boost
heterolog
vsvbase
vaccin
prior
challeng
differ
platform
anim
speci
use
might
account
differ
immun
respons
vaccin
hamster
femal
syrian
hamster
week
age
harlan
lab
indianapoli
usa
administ
pfu
intraperiton
inject
ip
steril
medium
control
prepar
previous
publish
serum
sampl
obtain
indic
time
postvaccin
retroorbit
bleed
blood
centrifug
g
min
room
temperatur
serum
remov
frozen
measur
neutral
antibodi
either
month
vaccin
group
hamster
mockvaccin
vaccin
challeng
andv
two
hundr
focu
form
unit
ffu
andv
strain
equival
administ
ip
use
previou
studi
dilut
steril
medium
deliv
intranas
anim
inhal
isofluran
hamster
monitor
daili
sign
diseas
euthan
upon
show
sign
sever
clinic
diseas
day
post
challeng
time
termin
blood
sampl
collect
measur
serum
antibodi
measur
neutral
antibodi
respons
vaccin
serial
dilut
sera
mix
approxim
ffu
andv
incub
h
humidifi
chamber
mixtur
use
inocul
vero
cell
atcc
h
co
inoculum
remov
carboxymethylcellulos
modifi
eagl
medium
mem
contain
fb
ad
cell
incub
co
seven
day
later
immunofocu
assay
perform
sera
result
greater
reduct
foci
consid
posit
frnt
previous
describ
examin
whether
hamster
surviv
challeng
day
post
inocul
develop
antiandv
antibodi
perform
elisa
detect
antibodi
direct
andv
nucleocapsid
protein
n
describ
previous
determin
whether
vaccin
result
signific
protect
andvinduc
diseas
compar
surviv
curv
mockvaccin
anim
use
logrank
mantelcox
test
signific
set
analysi
perform
use
prism
softwar
version
graphpad
softwar
inc
la
jolla
ca
usa
work
andvinfect
hamster
potenti
infecti
materi
conduct
facil
rocki
mountain
laboratori
divis
intramur
research
nation
institut
allergi
infecti
diseas
nation
institut
health
sampl
remov
perform
accord
approv
standard
oper
procedur
anim
experi
approv
institut
anim
care
use
committe
perform
follow
guidelin
associ
assess
accredit
laboratori
anim
care
aaalac
certifi
staff
aaalacapprov
facil
vaccin
hamster
singl
dose
vsvbase
andv
vector
provid
longterm
protect
lethal
viru
challeng
month
administr
shown
vaccin
high
degre
efficaci
administ
day
pre
day
postchalleng
indic
use
emerg
situat
laboratoryacquir
infect
might
prove
viabl
declin
neutral
antibodi
month
indic
durabl
vaccin
singledos
applic
least
hamster
question
booster
immun
might
improv
durabl
vaccin
candid
although
diseas
model
yet
develop
hcpscaus
hantavirus
evalu
vaccin
approach
specif
measur
antibodi
respons
could
warrant
nondiseas
anim
model
